story of the week
Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With HER2+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Study of Efficacy, Toxicity, and the Potential Impact of Genomic Alterations on Response to Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Human Epidermal Growth Factor Receptor 2 (HER2)+ Metastatic Breast Cancer
Breast Cancer Res Treat 2021 Jul 24;[EPub Ahead of Print], SM Balch, I Vaz-Luis, T Li, N Tayob, E Jain, K Helvie, JE Buendia-Buendia, E Shannon, SJ Isakoff, NM Tung, IE Krop, NU Lin, N Wagle, RA FreedmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.